Clear Scientific Presents at 88th Annual Scientific Meeting of the College on Problems of Drug Dependence
Updated: Sep 3
Portland, OR | June 2026
Piercen Oliver PhD, VP of R&D and Xinhua Li PhD, Executive Vice President Drug Development of Clear Scientific Inc. presented at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in Portland, Oregon, June 13th-17th.
CPDD provides a national and international forum for scientists of diverse backgrounds to advance the understanding of molecular-neurobiological aspects of addictive disorders and improve and develop treatments using novel behavioral and pharmacological therapies.
Piercen Oliver spoke on a NIDA-led panel about reducing animal testing and adopting human-relevant new approach methodologies (NAMs) to develop medications for substance use disorders. His talk was titled “Challenges in Nonclinical Studies Required to Evaluate the Safety and Efficacy of CS-1103, a Promising Drug Candidate for Acute Methamphetamine and Fentanyl Intoxication.”
Xinhua Li spoke on a panel about developing sequestrant-based therapeutics for substance use disorders and drug overdose. His talk was titled “Targeted Detoxification: Development of a New Therapeutic for Acute Drug Overdose.”
About Clear Scientific:
Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland.
Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals.
About CS-1103:
CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. Clear Scientific is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of drug fatalities in the US. The Company’s pipeline includes indications in substance use disorder, central nervous system (CNS) and metabolic diseases amongst others. CS-1103 is investigational and has not been approved by any health authority.
For more information, visit https://www.clearsci.com
Comments